An Independent US FDA: Gottlieb Supports Position, But Is Pessimistic About Prospects
Executive Summary
In an interview with the Pink Sheet, Scott Gottlieb agrees with other ex-commissioners that there are benefits to an independent agency, but he thinks political forces would prevent it from ever happening.
You may also be interested in...
Ex-Commissioners See Mostly Positives In Public View Of US FDA After COVID
Three of the US FDA’s former leaders believe the agency is coming through COVID with its reputation intact. They still support making the agency independent of the broader Health & Human Services Department, but the urgency may be gone.
Time For Independent US FDA? COVID Political Pressure Reignites Debate
The political spotlight on the FDA during the coronavirus pandemic has renewed a long-standing debate as to whether it should be made an independent, Cabinet-level federal agency and freed from direct HHS oversight.
Renewed Political Pressure on Hydroxychloroquine for COVID Highlights Need For Independent US FDA
Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.